Start Searching Today!

Type a URL to search registration information about any website

FIRAZYR Sign Up Information

Last Updated:

7/2/2020 1

Site Encrypted:

Yes

Site Category:

Email Verified:

VISIT SITE VIEW PRIVACY POLICY VIEW TERMS OF SERVICE

42/100

Data Held

Email Address

Your Name

First Name, Last Name

Your Address

Home Address, City, State, Zipcode

Phone Number

Phone

Post-Registration Data

We are still gathering data about this website

Validation

This site did not show evidence of storing passwords in plaintext.

This site does allow secured connections (https)

This site did show a clear way to unsubscribe from their emails

This site does verify your email address.

Membership Emails

Below is a sample of the emails you can expect to receive when signed up to FIRAZYR.

Explore the latest clinical da...

Rediscover prevention at our virtual booth

Important Safety Information

Full Prescribing Information

Patient Information

Visit our virtual booth

Reimagine What''s Possible at the TAKHZYRO Booth

We hope that you will join us for exciting happenings at this year''s TAKHZYRO booth, where you can:

•

Discover the data

•

See patient stories

•

Hear from experts

Check out the Expert Perspectives booth feature

Hear from Marc Riedl, MD, and William Lumry, MD, as they discuss TAKHZYRO, the first and only mAb in hereditary angioedema (HAE). These experts take you on a deep-dive of 2 clinical studies and explain how the data could be meaningful for your ≥12 years old patients with HAE.¹ Additionally, Dr. Riedl and Dr. Lumry will answer common questions about TAKHZYRO during the presentation.

To access the Takeda booth, you must be registered for the virtual 2020 ACAAI Annual Scientific Meeting.

VISIT OUR BOOTH

ACAAI=American College of Allergy, Asthma & Immunology.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-800-828-2088, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

Please see full Prescribing Information.

Reference: 1. TAKHZYRO (lanadelumab-flyo) [prescribing information]. Lexington, MA: Shire LLC; 2018.

Privacy Policy	Legal Notice	Contact Us
Takeda	Unsubscribe	TAKHZYRO

TAKEDA and the TAKEDA logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. TAKHZYRO is a registered trademark of Dyax Corp., a Takeda company.

US-LANA-0275v1.0 10‌/20

Raw Data Registration Structure Registration Form Text

Registration

* Name of Practice Why are you asking this?

First name

Last name

Phone

Home address

City

State

Zipcode

Select a State

Data Name	Data Type	Options
* Name of Practice Why are you asking this?	Text Box
First name	Text Box
Last name	Text Box
Email	Text Box
Phone	Text Box
Home address	Text Box
City	Text Box
State	Text Box
Zipcode	Text Box
	dropdown	Select a State
	dropdown	Select a State

Comments about firazyr

No Comments

Comment by: admin

Comment on: 01/09/2020